The abstract is read at the publisher; the summary is JClub's.
Pre-treatment plasma cell-free RNA signatures reflecting lymph node-like tumor microenvironments are elevated in responders to axicabtagene ciloleucel in 91 large B cell lymphoma patients.
- Why it matters: Durable CAR T responses in large B cell lymphoma vary, and clinicians lack reliable, minimally invasive predictors of 1-year outcome to guide management and adjunct strategies.
- What they did: The study profiled pre-treatment plasma cfRNA from 91 LBCL patients receiving axicabtagene ciloleucel, comparing responders versus non-responders and contrasting plasma cfRNA with PBMCs.
- The result: Unbiased analyses identified additional cfRNA signatures linked to 1-year clinical outcomes, supporting plasma cfRNA as a surrogate for tumor microenvironment state for risk stratification and potential TME-modulating adjunct therapies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.